Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Patients who have had chemotherapy, radiotherapy, experimental therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade =\< 1 or baseline) from clinically significant adverse events due to agents administered more than 4 weeks earlier (alopecia excluded); clinical significance to be determined by investigator

Patients may not be receiving any other investigational agents

Patients who have received prior treatment with any other VEGF signaling pathway inhibitors (e.g., bevacizumab, sorafenib, pazopanib, AZD2171, PTK787, VEGF Trap, etc.) are ineligible

History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib or bevacizumab

Patients with QTc prolongation (defined as a QTc interval greater than or equal to 500 msec) or other significant electrocardiogram (ECG) abnormalities (per investigator discretion) are excluded

Patients who require use of therapeutic doses of Coumarin-derivative anticoagulants such as warfarin are excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis; Note: full-dose low-molecular weight heparin (or other blood thinners) will be excluded as well given potential for bleeding with this regimen; prophylactic doses of low-molecular weight heparin (LMWH) will be allowed if prothrombin time (PT)/international normalized ratio (INR) is =\< 1.5

Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain sunitinib tablets are excluded

Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at a visit prior to enrollment is less than 140/90 mmHg

Patients with clinically significant cardiovascular disease are excluded

* Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry

* History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry

* Serious and inadequately controlled cardiac arrhythmia

* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)

* Clinically significant peripheral vascular disease

* History of pulmonary embolism within the past 12 months

* Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system

Patients with any of the following conditions are excluded:

* Serious or non-healing wound, ulcer, or bone fracture

* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 1

Because sunitinib is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) liver enzyme, the eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the principal investigator; every effort should be made to change medication regimens to include only those that do not affect CYP3A4, particularly patients who are taking enzyme-inducing anticonvulsant agents; any identified agent must be stopped at least 2 weeks prior to study registration

Use of agents with proarrhythmic potential (including but not limited to: terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide) are not permitted during the study; a comprehensive list of agents with proarrhythmic potential can be found at http://azcert.org

Steroid use is not recommended during sunitinib treatment unless absolutely necessary (e.g., for treatment of adverse events or protocol-required premedication) because many steroids (e.g., prednisone, prednisolone, dexamethasone, etc.) effectively lower sunitinib exposure through CYP3A4 interactions; patients currently using steroids must be discussed with investigator prior to enrollment

Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible; patients with a history of hypothyroidism are eligible provided they are currently euthyroid

Patients with known brain metastases should be excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements are ineligible

Pregnant (positive pregnancy test) women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib malate

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Evidence of a bleeding diathesis or coagulopathy

Invasive procedures defined as follows:

* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy

* Core biopsy within 7 days prior to day 1 therapy

* It is also appropriate to exclude subjects for whom there is the reasonable possibility that they will require major surgical procedures during the trial

Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies

For subjects with lung cancer, the following exclusions apply:

* Lung carcinoma of squamous cell histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable)

* History of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 3 months prior to study enrollment

* Current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin)

* Current or recent (within 10 days of enrollment) use of aspirin (\>325 mg/day) or chronic use of other nonsteroidal anti-inflammatory drugs (NSAIDs)

Subjects with a history of thrombotic microangiopathy are excluded

What this study is about